SBI Securities’s Grace Therapeutics GRCE Stock Holding History

SBI Securities’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$324	Sell	70 -31	-31%	-$122	﹤0.01%	3050
2025 Q4	$349	Hold	101	–	–	﹤0.01%	3007
2025 Q3	$301	Hold	101	–	–	﹤0.01%	3187
2025 Q2	$300	Hold	101	–	–	﹤0.01%	3179
2025 Q1	$230	Buy	101 +100	+10,000%	+$315	﹤0.01%	3172
2024 Q4	$4	Buy	+1	New	+$3	﹤0.01%	4025

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

SBI Securities's GRCE Position: Q1 2026 in Review

SBI Securities reduced its Grace Therapeutics (GRCE) stake by 31% in Q1 2026, selling an estimated $122 and leaving 70 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

SBI Securities first reported a position in GRCE in Q4 2024 and has held it in 6 quarters since. The position peaked at $349 in Q4 2025. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

SBI Securities held 70 shares of Grace Therapeutics worth $324 as of Q1 2026.
SBI Securities sold 31 Grace Therapeutics shares in Q1 2026, an estimated $122.
Grace Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3050 holding.
SBI Securities first reported a position in Grace Therapeutics in Q4 2024 and has held it in 6 quarters since.
SBI Securities's Grace Therapeutics position peaked at $349 in Q4 2025.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.